Navigation Links
Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
Date:6/25/2008

p>

About RDEA806

RDEA806 is a novel non-nucleoside reverse transcriptase inhibitor (NNRTI) for the potential treatment of HIV infection. Based on preclinical and clinical studies to-date, Ardea believes that RDEA806 may have important competitive advantages. These include the potential for potent antiviral activity against a wide range of HIV viral isolates, including those that are resistant to efavirenz (Sustiva(R)) and other currently available NNRTIs; a high genetic barrier to resistance; no reproductive toxicity based on animal studies; the potential to be administered in a patient-friendly, oral dosing regimen; limited pharmacokinetic interactions with other drugs; and the ability to be co-formulated with other HIV antiviral drugs.

About Ardea Biosciences

Ardea Biosciences, Inc., of San Diego, California, is a biotechnology company focused on the discovery and development of small-molecule therapeutics for the treatment of HIV, cancer and inflammatory diseases, including gout. We have four drug candidates in clinical trials and others in preclinical development and discovery. Our most advanced development candidate is RDEA806, a non-nucleoside reverse transcriptase inhibitor (NNRTI), which has completed a Phase 2a study for the treatment of HIV. We have evaluated our second-generation NNRTI for the treatment of HIV, RDEA427, in a human micro-dose pharmacokinetic study and have selected it as a development candidate. RDEA594, our lead development candidate for the treatment of gout, is in preclinical development and is believed to be an inhibitor of the URAT1 transporter in the kidney, which is responsible for regulation of uric acid levels. We are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1 study in advanced cancer patients, as well as in a Phase 1 study in normal healthy volunteers as a precursor to trials in patients with inflammatory diseases. Lastly, we have evaluated our second- generation MEK inhibitor for the treatmen
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
2. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
3. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
4. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
5. Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus
6. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load
7. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
8. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
9. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
10. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
11. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Calif. , Aug. 20, 2014 ... will be using advanced, ventilator technology from Covidien ... to care for patients. The ... more naturally, compared to conventional mechanical ventilation, and ... soon as possible. Patients on mechanical ventilation are ...
(Date:8/20/2014)... Aug. 20, 2014 Children aren,t the ... vaccinations to help prevent disease. The Centers for ... all adults, but currently, many adults are not ... National Immunization Awareness Month, and the American Lung ... especially those with lung disease, to talk with ...
(Date:8/20/2014)... -- Research and Markets  has announced the addition of ... their offering. Global Market Report of Pralmorelin ... and regionally ( Europe , Asia ... Latin America etc.). It captures Pralmorelin market trends, ... on three primary areas; manufacture methods & technology development, market ...
Breaking Medicine Technology:Torrance Memorial Medical Center Acquires Advanced Ventilator Technology to Enhance Patient Care 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 2American Lung Association Urges Adults with Lung Disease to Consult their Health Care Provider to Stay Current on Vaccinations 3Global Market Report of Pralmorelin 2
(Date:8/20/2014)... TUESDAY, Aug. 19, 2014 (HealthDay News) -- A group ... to get a flu shot. According to the ... released in recent years have upheld the safety and ... virus is highly infectious and can be particularly dangerous ... labor, and other complications," Dr. Laura Riley, chair of ...
(Date:8/20/2014)... than 42 percent of women underwent breast reconstruction ... associated with foregoing reconstruction included being black, having ... Author: Monica Morrow, M.D., of the Memorial Sloan ... Background: The Women,s Health and Cancer Rights Act ... following a mastectomy. Still, most women who undergo ...
(Date:8/20/2014)... Hundreds of Mirena IUD lawsuits ( http://www.themirenalawsuitcenter.com/ ... allegedly injured due to spontaneous migration of the IUD ... Superior Court, Bernstein Liebhard LLP reports. According to a ... Court has established procedures regarding the production of sales ... of the proceeding’s initial disposition pool. (In Re: Mirena ...
(Date:8/20/2014)... Thompson HealthDay Reporter WEDNESDAY, ... older women avoid a condition that causes a life-threatening irregular ... had a 10 percent lower risk of developing atrial fibrillation, ... the Aug. 20 issue of the Journal of the ... against the heart rhythm disorder even if they were obese, ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Park Cities ... 2014 NAPPS Presents 4 Pets supply donation drive that benefits ... is a national campaign that coincides with the Humane Society ... observed November 2nd through 8th, 2014. , As part of ... pet supply and monetary donations for the Presents 4 Pets ...
Breaking Medicine News(10 mins):Health News:All Pregnant Women Need Flu Shot: Ob/Gyn Group 2Health News:Patient perspectives on breast reconstruction following mastectomy 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 2Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 3Health News:Mirena Lawsuit News: Case Management Order Issued in New Jersey Mirena Litigation, Bernstein Liebhard LLP Reports 4Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 2Health News:Exercise May Guard Against Irregular Heartbeat in Older Women 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 2Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 3Health News:Dallas-based Park Cities Pet Sitter Announces Participation in the 2014 National Association of Professional Pet Sitters “Presents 4 Pets” Program 4
... Oncology (ASTRO) has selected a pediatric cancer survivor, Bella Rodriguez-Torres, ... presented with her award and $1,000 during the Awards Ceremony ... Annual Meeting in Miami Beach, Fla. , The Survivor Circle ... area who has devoted his or her time to helping ...
... ,Cannabinoids (marijuana) administration after experiencing a traumatic event blocks ... rats, according to a new study conducted at the ... Neuropsychopharmacology . "We found that there is a ... deal with symptoms simulating PTSD in rats," said Dr. ...
... used antipsychotic drugs in managing agitation in patients with dementia ... shows. The first major study of the impact of ... in dementia patients found both short term and persisting decrease ... Research Fellow in the School of Psychiatry at the University ...
... News) -- Differences in the genetic makeup of prostate cells ... more likely to get prostate cancer and die from it ... a lot of socioeconomic and environmental factors that create differences ... co-author Bi-Dar Wang, assistant research professor of pharmacology and physiology ...
... Women whose first pregnancy ended in infant death are ... new research published today (21 September) in BJOG: ... Black women experienced the highest rates of stillbirth in ... University of South Florida and the University of Rochester ...
... Move over, gourmet meal. Apparently cold hard cash and a ... conclusion of new research that examined how people react when ... people salivate when they desire material objects, according to the ... Research . "Merely being exposed to the concept of ...
Cached Medicine News:Health News:Courageous 8-year-old honored with 2011 Survivor Circle Award 2Health News:Marijuana administration after a traumatic experience prevents post-traumatic stress symptoms 2Health News:Humor as effective as medication in treating agitation in dementia 2Health News:Genes May Explain Blacks' Bleaker Prostate Cancer Stats 2Health News:Infant mortality linked to subsequent risk of stillbirth finds new US study 2Health News:Infant mortality linked to subsequent risk of stillbirth finds new US study 3Health News:Cash, Luxury Goods Really Do Get People Salivating: Study 2
... Cascade M-4 is a manual ... all routine clotting assays - PTs, ... Designed for easy, inexpensive, low-volume testing, ... but big on features, offering time ...
... STA is a fully-automated, coagulation workstation ... immunological assays in true random access ... sample management offers high throughput and ... the need to interrupt current testing. ...
... ACL Advance can reduce costs ... lab. With its superior ACL ... easy to use coagulation analyzer ... Plus, the protective transparent cover ...
... Pro Professional Hemoglobin Testing System consists of ... strips, used in measuring total hemoglobin, from ... Pro provides the precision, accuracy and cost ... Pro Professional Hemoglobin Testing System is portable ...
Medicine Products: